ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Translational Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1692250
This article is part of the Research TopicEmerging Targeted and Immunotherapeutic Strategies in Oncology: From Solid Tumors to Hematologic MalignanciesView all 7 articles
Anticancer activity of MDM2 inhibition in 2D and bioprinted 3D retinoblastoma cell models
Provisionally accepted- 1Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy
- 2LTTA Centre, University of Ferrara, Ferrara, Italy
- 3Department of Translational Medicine, University of Ferrara, Ferrara, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Retinoblastoma is the most common childhood tumor affecting the retina. Pharmacological resistance or delayed intervention leads to loss of vision. Therefore, novel therapeutic strategies need to be assessed in preclinical models that mimic the in vivo tumor. This project aims to investigate the anticancer activity of the MDM2 inhibitor, nutlin-3a, in the treatment of retinoblastoma using both conventional 2D in vitro models and more-realistic 3D bioprinted models. Unlike many cancers, retinoblastoma presents a p53 wild-type phenotype, making the p53 pathway a promising target for pharmacological treatment via MDM2 inhibitors. Initially, nutlin-3a was tested on Y79 and Weri-Rb1 retinoblastoma 2D cell lines cultures. A significant concentration-dependent reduction in cell viability was observed as early as 24 hours, associated with cell cycle blockade in both S and G2/M phases, assessed by cytofluorimetric analysis. Activation of the p53 pathway was observed by western blotting. Secondly, the same cell lines were used to generate innovative 3D bioprinted models using 2% alginate and 5% gelatin bioinks. The 3D structures were treated with nutlin-3a for 72 hours and assessed for viability using MTT or fixed and embedded in paraffin for histological and immunohistochemical investigation. Hematoxylin and Eosin staining of non-treated 3D structures evidenced an architecture similar to the primary tumor rosette formation. Interestingly, nutlin-3a treatment significantly reduced the dimension of rosettes in both 3D models; additionally, it reduced the number of rosettes in the Y79 3D model. These data were supported by a significant reduction in proliferation and a decrease in Ki-67 expression. Our 3D models closely resemble retinoblastoma tumor tissue and can serve as a platform to assess innovative drugs or implement the promising results on the use of MDM2 inhibitors for retinoblastoma treatment.
Keywords: Retinoblastoma, Nutlin-3a, Y79, WERI-RB1, Bioprinted model
Received: 25 Aug 2025; Accepted: 08 Oct 2025.
Copyright: © 2025 Bompan, Lodi, Foschi, Dipinto, COSENZA, Casciano, Severi, Sanvido, Caruso, Giari, Zauli, Voltan and Romani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Rebecca Voltan, rebecca.voltan@unife.it
Arianna Romani, arianna.romani@unife.it
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.